Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

AbbVie at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

AbbVie brings 3 presentations to SITC 2026 in Phoenix. Its program centres on engineered antibodies that block or redirect immune signals, including a drug that inhibits both PD-1 and VEGF. A concrete study shows that blocking GARP and TGF-beta with livmoniplimab boosts PD-1 inhibition in pieces of human tumor kept alive in the lab.

OrganizationSITC 2026 Attendance
AbbVie
North Chicago, IL
abbvie.com
Large pharma
A pharmaceutical company developing and marketing medicines, including cancer immunotherapies.
Poster
Fri Nov 6
12:15–1:45pm
5:30–7pm
Poster
Fri Nov 6
12:15–1:45pm
5:30–7pm
Talk
Fri Nov 6
3:00pm–3:10pm

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from AbbVie

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction